Could a diabetes pill boost chemo response in breast cancer? new study investigates.
NCT ID NCT05989347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looks at whether adding dapagliflozin, a diabetes drug, to standard chemotherapy changes insulin-related markers in the blood. It involves 20 women with early-stage HER2-negative breast cancer who also have high insulin levels. The goal is to gather safety data and understand how the drug affects insulin resistance, not to treat the cancer directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale Cancer Center Smilow Cancer Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?